---
title: "Immunome buys licensed Zentalis ROR1 assets for 1,805,502 shares"
url: "https://aibio.space/news/immunome-buys-licensed-zentalis-ror1-assets-1-805-502-shares/"
publisher: "aibio.space (Biotech Investor Relations News)"
date: "2024-10-29"
section: "Mergers"
tickers: "NASDAQ:IMNM"
source: "https://www.sec.gov/Archives/edgar/data/1472012/000110465924112053/tm2426946d1_8k.htm"
summary: "Immunome owes Zentalis $5,000,000 in cash only if a developmental milestone is achieved. The purchase ends the January 2024 license agreement."
---

By the aibio.space news desk.

Sources

- [Immunome, Inc. 8-K (2024-10-29)](https://www.sec.gov/Archives/edgar/data/1472012/000110465924112053/tm2426946d1_8k.htm)

[IMNM](https://aibio.space/companies/immunome/)

2024-10-29

# Immunome buys licensed Zentalis ROR1 assets for 1,805,502 shares

Tickers [IMNM](https://aibio.space/companies/immunome/)

Immunome owes Zentalis $5,000,000 in cash only if a developmental milestone is achieved. The purchase ends the January 2024 license agreement.

## Key facts

- **Company**: Immunome, Inc. (NASDAQ: IMNM)

- **News type**: Mergers

- **Primary source**: [Immunome, Inc. 8-K (2024-10-29)](https://www.sec.gov/Archives/edgar/data/1472012/000110465924112053/tm2426946d1_8k.htm)

*A conference room set for a meeting. CC0, via rawpixel. The picture shows the field, not the companies named.*

Immunome, Inc. ([IMNM](https://aibio.space/companies/immunome/)) disclosed in an 8-K that it bought the assets it had licensed from Zentalis Pharmaceuticals, Inc. On October 25, 2024, Immunome, Zentalis and Zeno Management, Inc., a wholly owned Zentalis subsidiary, signed an Asset Purchase Agreement. The assets include Zentalis' antibody-drug conjugate platform technology, ROR1 antibodies and ADCs targeting ROR1.

As consideration, Immunome issued Zentalis 1,805,502 shares of common stock. It must also pay Zentalis $5,000,000 in cash if a developmental milestone is achieved. That milestone was already part of the license agreement dated January 5, 2024, and Immunome agreed to use commercially reasonable efforts to reach it.

The license agreement ended automatically when the purchase closed, which ended Immunome's contingent milestone and royalty payment obligations under it. Certain accrued rights and obligations under the license agreement survive the closing.

Under a stock issuance agreement, Zentalis agreed to standstill restrictions that expire on the one-year anniversary of the agreement's effective date. Until the six-month anniversary of closing, Zentalis will hold and not sell more than 50% of the shares, subject to exceptions. Immunome agreed to use commercially reasonable efforts to file a resale registration statement within 30 days after closing.

The shares were issued under the Section 4(a)(2) exemption from registration.

[Report an error](https://aibio.space/reputation/#correction)

## Companies in this story

IMNM

Immunome, Inc.

NASDAQ · United States

Open the starter desk

## More in Mergers

Mergers

### [InMed sets November 5 record date for CVRs tied to Mentari merger](https://aibio.space/news/inmed-sets-november-5-record-date-cvrs-tied-mentari-merger/)

Oct 27, 2026

Mergers

### [Rallybio declares estimated $82.7 million cash distribution tied to Avenzo merger](https://aibio.space/news/rallybio-declares-estimated-82-7-million-cash-distribution-tied-avenzo/)

Oct 26, 2026

Mergers

### [Skye Bioscience files preliminary proxy for its Redx Pharma acquisition](https://aibio.space/news/skye-bioscience-files-preliminary-proxy-redx-pharma-acquisition/)

Oct 26, 2026

---
Source page: https://aibio.space/news/immunome-buys-licensed-zentalis-ror1-assets-1-805-502-shares/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Immunome buys licensed Zentalis ROR1 assets for 1,805,502 shares", 2024-10-29, https://aibio.space/news/immunome-buys-licensed-zentalis-ror1-assets-1-805-502-shares/